U.S., Sept. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07809594) titled 'CS1-Targeted CAR-T Cells for Relapsed/Refractory Multiple Myeloma' on July 29.
Brief Summary: This investigator-initiated, exploratory clinical trial is designed to evaluate the feasibility, safety, and preliminary antitumor activity of autologous CS1-targeted chimeric antigen receptor T (CAR-T) cells in adults with relapsed or refractory multiple myeloma (MM).
Multiple myeloma is a hematologic malignancy characterized by the clonal proliferation of plasma cells. Despite advances in treatment, patients with relapsed or refractory disease often have limited therapeutic options after multiple lines of therapy. CS1, also known as sig...